tbuckley/cabot-search huggingface dataset:
Stevens' cure for tuberculosis
Authors: M. L. Moss
Journal: Journal of the Royal Society of Medicine (2002)

Stevens' cure for tuberculosis I was fascinated by Dr Newsom's account of Stevens' cure (September 2002 JRSM 1 ).In 1927 my father was apparently close to death in Talgarth TB sanatorium, South Wales, with severe bilateral lung disease and multiple haemoptyses.He was considered too ill for the thoracoplasty operation fashionable at the time.His father, himself dying of TB, had advised him on his deathbed to try Stevens' cure and at this stage of his illness he did.His recovery started from that date.He never had another haemoptysis and within 3-4 years was able to obtain life insurance and marry.The medical examiner was said to have flung down his stethoscope in amazement, declaring 'no sign of disease at all'.My father continued to take the umckaloabo root on and off for years but never had another attack.The distinctive pungent odour of what seemed to be an infusion would often fill the house and signal that Dad was not feeling too good for some reason.He worked as a chemistry teacher till he was 65 with never a day 'off sick' and died of heart failure at 77.When I went to Oxford to read medicine in 1958 I was found, to my surprise, to be Mantoux-test negative.My father, who possessed a lot of newspaper articles and one of the books on Stevens' cure, thought the BMA had been very unfair to Stevens (a non-medic) and very unscientific in their approach to a much needed avenue of possible TB research.Perhaps today, with the widespread resistance to TB drugs, the root should be properly evaluated.
Sepsis
Authors: Huan J. Chang
Journal: JAMA (2010)

Sepsis Sepsis is a medical condition in which the immune system goes into overdrive, releasing chemicals into the blood to combat infection (microbes in the blood, urine, lungs, skin, or other tissues) that trigger widespread inflammation (cellular injury in body tissues).If the body is not able to regulate this immune response, it then overwhelms normal blood processes.The first mention of the word sepsis in a medical context was more than 2700 years ago in the poems of Homer.The word derives from the Greek word sepein, meaning "to rot."Sepsis occurs in 1% to 2% of all hospitalizations in the United States, affecting at least 750 000 persons and costing $17 billion per year to treat.A term sometimes used for sepsis is "blood poisoning," but there is no poison involved in sepsis.The February 24, 2010, issue of JAMA includes an article about possible treatments for early sepsis.
Selective Inhibition Mediates the Sequential Recruitment of Motor Pools
Authors: Maarten F. Zwart, Stefan R. Pulver, James W. Truman, Akira Fushiki, Richard D. Fetter, Albert Cardona, Matthias Landgraf
Journal: Neuron (2016)

(Neuron 91, 615–628; August 3, 2016) We regret and hereby correct the omission of Richard D. Fetter as an author, who performed sample preparation, serial sectioning and electron microscopy imaging of the whole Drosophila larval central nervous system, making possible the subsequent neuron reconstructions and synapse annotations of larval premotor circuits. We also acknowledge the Fly EM Project Team technicians who assisted R.D.F in imaging the serial sections with the statement: “We thank the Fly EM Project Team for assisting R.D.F. with imaging the serial sections of the larval central nervous system with transmission electron microscopy.” This has been corrected both online and in print. Selective Inhibition Mediates the Sequential Recruitment of Motor PoolsZwart et al.NeuronJuly 14, 2016In BriefHow locomotor systems generate overlapping sequences of local muscle contractions is unknown. Zwart et al. show in the Drosophila larva that an inhibitory neuron acts as a delay line to a specific population of motor neurons to generate such a sequence. Full-Text PDF Open Access
Caution About Cruises
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
OFFICIALS of the ASSOCIATION
Journal: JAMA (1972)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
I am more than a body to stitch up and label
Authors: None Anonymous
Journal: BMJ (2021)

I am more than a body to stitch up and label This author describes the impact of self-harm and how support services have left her feeling rejected and dismissed. AnonymousI live with scars that are both highly visible and largely unseen.At the age of 16 I went on a diet so that I would feel less noticeable.I was diagnosed with anorexia nervosa and spent the next three years being re-fed as an inpatient.Since losing control of my weight, I started another secretive and self-destructive action.
ACTR-63. TREATMENT AND SURVIVAL OF PATIENTS WITH LOWER GRADE GLIOMA ACCORDING TO THE 2007 AND THE 2016 WHO CLASSIFICATION: A RETROSPECTIVE ANALYSIS OF 423 PATIENTS
Authors: Eike Steidl, Pia Zeiner, Marlies Wagner, Emmanouil Fokas, Marie-Therese Forster, Michael Ronellenfitsch, Joachim Steinbach, Patrick Harter, Oliver Baehr
Journal: Neuro-Oncology (2018)

INTRODUCTION: Classification as well as treatment of patients with lower grade gliomas (°II+°III) have changed fundamentally during the last years. Molecular markers have augmented diagnostic workup and combined radiochemotherapy was established for most of the subgroups. However, molecular markers have not been part of the inclusion criteria of most of the relevant clinical trials. Larger analyses outside of clinical trials are rare. MATERIALS AND We screened our clinical cancer database for patients with lower grade glioma newly diagnosed from 1995 to 2015. We identified 774 patients of whom 345 had to be excluded, resulting in an evaluable cohort of 423 patients. We evaluated general characteristics, morphological diagnosis, molecular markers, treatment, time-to-treatment-failure (TTF; initiation of a new treatment or death) and overall survival (OS). According to the 2007 WHO classification our cohort included 145 (34.3%) Astrocytoma WHO °II, 56 (13.3%) Oligoastrocytoma/Oligodendroglioma WHO °II, 129 (52.5%) Astrocytoma WHO °III and 93 (22.0%) Oligoastrocytoma/Oligodendroglioma WHO °III. In 235 patients we were able to molecularly classify the tumors based on the 2017 WHO classification using IDH status and 1p/19q or ATRX status. Patients with a molecularly defined Oligodendroglioma showed a median TTF of 5.2, 4.2 and 7.8 years for radiotherapy, chemotherapy and radiochemotherapy, respectively. Patients with a molecularly defined Astrocytoma showed a median TTF of 1.6, 2.9 and 6.7 years for radiotherapy, chemotherapy and radiochemotherapy, respectively. In IDH wildtype tumors TTF was below 12 months without relevant differences. Treatment with combined radiochemotherapy resulted in markedly improve TTF in molecular defined oligodendroglioma and astrocytoma compared with either radiotherapy or chemotherapy alone. Due to the short follow-up of 5.3 years (mean) median OS has not been reached for any of the IDH mutant subgroups. Combined treatment with radiotherapy and chemotherapy resulted in markedly improved TTF in patients with molecularly defined oligodendroglioma and astrocytoma.
Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with <i>IDH 1/2</i> Mutations
Authors: Daniel A. Pollyea, Courtney D. Dinardo, Martha L. Arellano, Arnaud Pigneux, Walter Fiedler, Marina Konopleva, David A Rizzieri, B. Douglas Smith, Atsushi Shinagawa, Roberto M. Lemoli, Monique Dail, Yinghui Duan, Brenda J. Chyla, Jalaja Potluri, Jean A Ridgeway, Hagop M. Kantarjian
Journal: Blood (2020)
A Correction
Journal: BMJ (1899)

Aspiration of the joint, followed by firm pressure obtained by wool pads, and a bandage, and the fitting of a "calliper" Thomas's knee splint so that the patient can get about, is often a successful, measure in such a case.Incision and washing out has been practised, but there is often a tendency to recurrence alter this operation, though many cases are reported as cured.SALINE INJECTIONS IN COLLAPSE.E. D.
Clinical treatment pathways utilization in an outpatient academic cancer center.
Authors: Anna Chen, Seojin Park, Valerie Pracilio Csik, Vittorio Maio, Karen Walsh, Adam F Binder
Journal: Journal of Clinical Oncology (2021)

323 Background: Clinical treatment pathway (CTP) tools have been incorporated into oncology practices to help standardize treatment, reduce care variation in cancer patients, and move towards value-based care. CTP tools incorporate the latest guidelines and are developed through multidisciplinary committees. Treatment decisions are prioritized by efficacy, toxicity, and cost to improve quality and value. This is especially important in cancer care which is associated with high drug costs. However, use and implementation of CTP tools has been met with mixed reviews and published data from academic medical centers are limited. Methods: Outpatient treatment decisions for patients across different cancer types, including colorectal, gastroesophageal, and breast cancers from July 2018 to March 2020 at an urban NCI-designated cancer center were evaluated. Every treatment decision was evaluated in relation to physician utilization of CTP tools. Treatment decisions were categorized as choosing a CTP recommended option ( pathways dependent), not choosing a CTP recommended option ( pathways independent), or not using the CTP tool at all ( non-pathways). Descriptive statistics and significance testing were used to explore CTP utilization over time, physician years in practice, cancer type, and cancer stage. Multinomial and binary logistic regression models were used to evaluate associated factors with CTP utilization. Results: During the study period, 1,007 treatment decisions were identified. Of these, 76% were pathways dependent, 13% were pathways independent, and 11% were non-pathways. CTP utilization was statistically significant in association with cancer type, cancer stage, physician years in practice, and year of encounter. In multinomial logistic regression models, physicians with more years in practice were more likely to be pathways independent and non-pathways than pathways dependent. Physicians treating colorectal or gastroesophageal cancer were more likely to be pathways independent [OR 3.27; 95% CI: 1.98-5.42 and OR 2.25; 95% CI: 1.12-4.49, respectively] or non-pathways [OR 2.98; 95% CI: 1.65-5.37 and OR 3.21; 95% CI: 1.58-6.54, respectively] than pathways dependent compared to physicians treating breast cancer. Treatment decisions for patients with either stage 2 and stage 4 cancers were more likely to be pathways independent than stage 1 cancers [OR 4.13; 95% CI: 1.44-11.84 and OR 4.37; 95% CI: 1.27-15.04, respectively]. Conclusions: This study found that a large proportion of treatment decisions for patients across different cancer types were made utilizing CTP tools, but utilization varies according to cancer type, stage, and physician years in practice. Further research is needed to better understand the physician decision making process and implementation of CTP tools to drive improvement in design, education, and training.
Trial etiquette.
Authors: J G McVie
Journal: Journal of Clinical Oncology (1997)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1997.15.7.2761 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 9215853 Trial etiquette. J G McViexJ G McVieSearch for articles by this author https://doi.org/10.1200/JCO.1997.15.7.2761 PDF "Trial etiquette.." Journal of Clinical Oncology, 15(7), pp. 2761–2762© 1997 by American Society of Clinical Oncology
Functional Living Trileaflet Heart Valves Grown In Vitro
Authors: Simon P. Hoerstrup, Ralf Sodian, Sabine Daebritz, Jun Wang, Emile A. Bacha, David P. Martin, Adrian M. Moran, Kristine J. Guleserian, Jason S. Sperling, Sunjay Kaushal, Joseph P. Vacanti, Frederick J. Schoen, John E. Mayer
Journal: Circulation (2000)

Background —Previous tissue engineering approaches to create heart valves have been limited by the structural immaturity and mechanical properties of the valve constructs. This study used an in vitro pulse duplicator system to provide a biomimetic environment during tissue formation to yield more mature implantable heart valves derived from autologous tissue. Methods and Results —Trileaflet heart valves were fabricated from novel bioabsorbable polymers and sequentially seeded with autologous ovine myofibroblasts and endothelial cells. The constructs were grown for 14 days in a pulse duplicator in vitro system under gradually increasing flow and pressure conditions. By use of cardiopulmonary bypass, the native pulmonary leaflets were resected, and the valve constructs were implanted into 6 lambs (weight 19±2.8 kg). All animals had uneventful postoperative courses, and the valves were explanted at 1 day and at 4, 6, 8, 16, and 20 weeks. Echocardiography demonstrated mobile functioning leaflets without stenosis, thrombus, or aneurysm up to 20 weeks. Histology (16 and 20 weeks) showed uniform layered cuspal tissue with endothelium. Environmental scanning electron microscopy revealed a confluent smooth valvular surface. Mechanical properties were comparable to those of native tissue at 20 weeks. Complete degradation of the polymers occurred by 8 weeks. Extracellular matrix content (collagen, glycosaminoglycans, and elastin) and DNA content increased to levels of native tissue and higher at 20 weeks. Conclusions —This study demonstrates in vitro generation of implantable complete living heart valves based on a biomimetic flow culture system. These autologous tissue-engineered valves functioned up to 5 months and resembled normal heart valves in microstructure, mechanical properties, and extracellular matrix formation.
ABSORPTION AND STORAGE OF VITAMIN A
Journal: JAMA (1935)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Mammographic screening of elderly women
Authors: S. A. Feig
Journal: JAMA (1996)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Putting cholesterol control on a diet
Journal: JAMA (1989)

<h3>To the Editor.—</h3> In the July 7 issue Dr Palumbo<sup>1</sup>editorializes on the cost for screening and treatment of cholesterol levels in the entire population. Careful observers of the letters sections of several journals will have noted a thin stream of protests from various parts of the country, over the last several years, regarding the numbing costs of the great cholesterol public health initiative, if applied as recommended by the National Cholesterol Education Program. It seems that at last some of those considerations have come to the attention of mainstream academia. I only regret that such considerations have followed, rather than preceded, the publication of the National Cholesterol Education Program, which may produce the largest collection of malpractice litigation ever seen in this country if the courts come to agree that failure to apply the explicit algorithms and recommendations constitutes negligence. The fact that the program contains a disclaimer
Abstract 14069: Subclinical Impairment of Left Ventricular Function in Stage A Subjects in a Community-based Population
Authors: Takuya Hasegawa, Masanori Asakura, Hideaki Kanzaki, Hiroshi Asanuma, Seiji Takashio, Makoto Amaki, Hiroyuki Takahama, Takahiro Ohara, Yasuo Sugano, Satoshi Yasuda, Hisao Ogawa, Toshihisa Anzai, Masafumi Kitakaze
Journal: Circulation (2015)

Introduction: Stage A heart failure (HF) is defined as an asymptomatic state with HF risk factors of hypertension, diabetes, obesity, metabolic syndrome, and atherosclerotic disease in the absence of obvious left ventricular (LV) structural changes including LV hypertrophy (LVH). ACC/AHA guidelines recommend us to treat these risk factors of Stage A HF patients to prevent the progression of HF, hinting us to investigate the prevalence of subclinical impairment of LV function in Stage A subjects in general populations. Methods: We studied 1162 community-dwelling subjects without obvious heart diseases (mean age, 63±11 years; 448 men, 714 women, 63% with hypertension and 11% with diabetes) in the annual health checkup in a rural community, Arita-cho, Saga, Japan. The population was divided into 3 groups; the subjects without either LVH or the HF risk factors ("Stage 0"), the subjects with the HF risk factors in the absence of LVH (Stage A) , and the subjects in the presence of LVH (Stage B). LV systolic and diastolic function were estimated by mitral annular velocity in systole (s'), and the waves of transmitral flow (E) and mitral annular velocity (e'), respectively. LVH was defined as the top quintile of LV mass index. Results: The subjects in Stage A had the lower and higher values of s' and E/e', respectively, and the higher prevalence of LV diastolic dysfunction than those in Stage 0, while 45% of Stages A subjects showed LV diastolic dysfunction (Table). In multivariate logistic analyses, age, systolic blood pressure and LV mass were independent determinants of s', whereas either overlapped or different risk factors, such as age, sex, systolic blood pressure, and body mass index emerged as the determinants for E/e'. Conclusions: Even without obvious LV remodeling, subclinical LV systolic and diastolic impairment was observed in Stage A subjects. The disparity of the risk factors between LV systolic and diastolic dysfunction may indicate their pathophysiological differences.
Duplication of the inferior vena cava and its role in recurrent pulmonary emboli
Authors: M. Wagner
Journal: JAMA (1969)

Recurrent thromboembolism occurred in a 67-year-old man and an inferior caval ligation was performed. Phlebography showed a supplementary left vena cava. A secondary left caval ligation was performed and the patient had an uneventful recovery and no further incident.
Under the Influence or If You Drink Don't Meet
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal